RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's AGN DARPin may solidify the longer-term market position for Regeneron's REGN Eylea.
The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's."
RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019.
RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst Ratings
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in